Letter

ASCOT: a tale of two treatment regimens

BMJ 2005; 331 doi: 10.1136/bmj.331.7523.1022-b (Published 27 October 2005)
Cite this as: BMJ 2005;331:1022.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Odds are that it's hype

  1. Martin G Duerden, general practitioner (martin@theduerdens.co.uk)
  1. Meddygfa Gyffin, Conwy LL32 8LT

    EDITOR—The editorial on ASCOT seems to back hype rather than evidence based medicine.1 The 2004 update of the British Hypertension Society's guideline recommends first line use of angiotensin modifying drugs in non-black people younger than 55,apparently on the basis of a study with 56 patients that looked at blood pressure response.2 The contemporaneous recommendations from the National Institutefor Health and Clinical …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular